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A QUALITATIVE STUDY OFTHE INDIVIDUALISED IMPACT OF
RESTLESS LEGS SYNDROME (RLS) ON QUALITY OF LIFE
Speight J, Reaney M, Showumni O
AHP Research Ltd, Uxbridge, Middlesex, UK
OBJECTIVES: Restless Legs Syndrome (RLS) is a neurological
movement disorder characterised by uncomfortable leg sensa-
tions when at rest, exacerbated in the evening/at night, and
alleviated by movement. A systematic literature review demon-
strated the need for a new RLS-speciﬁc QoL instrument. This
interview study forms the second step in instrument develop-
ment. METHODS: The Schedule for the Evaluation of Individual
Quality of Life (SEIQoL) was used to identify aspects of life that
are most important for individuals’ QoL, rank their relative
importance and then rate them in terms of impact by RLS. We
adapted the SEIQoL to be RLS-speciﬁc and suitable for telephone
administration. Twenty-six participants (mean age 61 years
(range 32–83 years); 58% female) were recruited from the
Ekbom Society, the UK’s RLS patient support group. Telephone
interviews (mean duration 54 mins (range 31–83 mins)),
included the adapted SEIQoL and semi-structured questions
about experience of RLS and its treatment. RESULTS: The
adapted SEIQoL was acceptable to participants and facilitated an
individualised investigation of the impact of RLS on QoL. On
average, participants had experienced RLS symptoms for 22
years (range: 6 months to 65 years), though 35% had never
received a diagnosis from their doctor. Most participants
described their symptoms as severe (73%) and occurring daily
(88%). General aspects of life impacted by RLS included family,
health, hobbies, spirituality and social life, as well as some areas
that may be more speciﬁc to living with RLS (physical ability,
stress and sleep). CONCLUSION: RLS had an adverse impact on
most aspects of life nominated by individuals as important for
their QoL. This study supports our previous literature review,
which indicated that QoL is impacted in many ways that are
important to the individual and rarely assessed in existing mea-
sures. These results will be used to develop a comprehensive
measure of the impact of RLS on QoL.
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(RLS) ON QUALITY OF LIFE: A SYSTEMATIC REVIEW
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OBJECTIVES: Restless Legs Syndrome (RLS) is a neurological
movement disorder affecting 5–15% of the general population.
Given its subjective nature, it is important to assess the impact of
RLS from the patient’s perspective. The objective of the literature
review was to identify and assess the suitability of instruments
used to measure the impact of RLS on quality of life (QoL).
METHODS: Systematic searches of Medline and PsycINFO were
conducted using terms synonymous with “RLS” in combination
with terms associated with measuring “QoL”. RESULTS: Two
hundred and six abstracts were identiﬁed and screened. Of these,
21 reported quantitative studies using a variety of measures (i.e.
generic health status, RLS-speciﬁc health status, symptoms and
emotional well-being, anxiety/depression and fatigue/sleep),
despite almost all abstracts referring to the measurement of
“QoL”. Generic measures, such as the SF-36 can be useful when
making comparisons with other medical conditions but have
limited value for assessing the full impact of RLS because they
include irrelevant items (e.g. mobility, which is likely to relieve
symptoms) and exclude relevant issues (e.g. impact on sleep,
working life). The RLS-speciﬁc symptom measure (the IRLS) is
often misinterpreted as measuring QoL rather than symptoms.
Recently, the RLSQOL and RLSQLI have been developed to
measure the impact of RLS on QoL. Despite displaying adequate
psychometric properties and assessing some facets of QoL
impacted by RLS, these also do not assess the full range of
aspects of life affected by RLS. CONCLUSION: This review
concludes that existing generic and RLS-speciﬁc measures are
likely to underestimate the full impact of RLS on QoL and,
therefore, underestimate the full potential beneﬁts of new treat-
ments. In addition, they rarely offer opportunities for patients to
indicate any perceived beneﬁts of the condition. A new question-
naire is needed to assess the full impact (both positive and nega-
tive) of RLS on QoL.
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OBJECTIVES: Guidance from European and U.S. regulatory
agencies regarding Patient Reported Outcomes (PROs) has
afforded greater clarity on various aspects of instrument develop-
ment. As no current measures of migraine Quality of Life (QoL)
impact have addressed issues related to prophylactic treatment,
the M-PACT was developed as a PRO tool to evaluate this aspect
of migraine-impacted QoL. The current abstract provides details
on the ﬁt of theM-PACTwith qualitative development guidelines.
METHODS: An exhaustive review of the literature was ﬁrst
conducted to identify pertinent PRO instruments or items.
Experts in migraine were gathered for additional input on the
domains and format of the PRO. Next, patient (i.e., migraineurs)
focus groups were held to understand the patient-perceived appli-
cability of domains as well as to generate item language. With the
introduction of EULA and FDA guidance documents during
development of the M-PACT, item anchors and test instructions
were reﬁned. The ﬁnal format of the M-PACT was evaluated by
experts in migraine and with migraine and headache sufferers
through cognitive interviews. RESULTS: The multiple modalities
of conceptual framework development yielded a total of 21 items
covering 4 related domains (daily activities, emotional stability,
concentration, and social interaction), all subsumed under a
single factor of migraine-related QoL impact. An overabundance
of items was speciﬁcally sought to allow for selection of the best
items during quantitative analysis ofM-PACT. Feedback from the
cognitive interviews conﬁrmed these questions as relevant and
easy to understand CONCLUSION: The M-PACT questionnaire
was developed following a sequential, multistep, multisource
approach for questionnaire development. Given the strong
synergy between key opinion leaders, migraineurs, and the litera-
ture, the M-PACT PRO is expected to be an effective measure to
assess QoL impact on migraineurs undergoing prophylactic treat-
ment. Quantitative validation of the M-PACT is underway.
Overall, the M-PACT ﬁts well with qualitative development
guidelines.
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A REVIEW OF PATIENT-REPORTED OUTCOMESTHAT
COMPLEMENT ASSESSMENTS OF SEIZURE REDUCTION IN
ADULT EPILEPSY DRUGTRIALS
Hoffman DL1, Mychaskiw MA2
1Deborah Hoffman, PhD, LLC, New Haven, CT, USA, 2Pﬁzer, Inc, New
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OBJECTIVES: 1) To identify patient-reported outcomes used to
complement assessments of seizure reduction in adult epilepsy
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